Advanced Clinical Trials in Shanghai, Shanghai Municipality
225 recruitingShanghai, Shanghai Municipality, China
Showing 1–20 of 225 trials
Recruiting
Phase 2
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Solid TumorsHER2 Mutation
Bayer111 enrolled54 locationsNCT06760819
Recruiting
Phase 1
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Breast CancerAdvanced Solid Tumor
BeOne Medicines86 enrolled27 locationsNCT07222267
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmHER2-negative Breast Cancer+7 more
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+2 more
Fudan University160 enrolled1 locationNCT06649331
Recruiting
Phase 1Phase 2
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer Stage IV+1 more
Forward Pharmaceuticals Co., Ltd.99 enrolled22 locationsNCT06064812
Recruiting
Phase 3
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Early-stage or Locally Advanced HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.740 enrolled2 locationsNCT07196774
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
HER2-positive Advanced Solid Tumor
DualityBio Inc.796 enrolled102 locationsNCT05150691
Recruiting
Phase 2
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
Antibody-drug ConjugatesAdvanced Solid Tumor CancerUrachal Cancer
Sheng Zhang90 enrolled1 locationNCT07309770
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 3
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 3
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
Locally Advanced Breast Cancer
RenJi Hospital316 enrolled1 locationNCT04254263
Recruiting
Phase 1Phase 2
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Breast CancerNon-small Cell Lung CancerAdvanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.414 enrolled20 locationsNCT07169994
Recruiting
Phase 1
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Breast CancerOvarian CancerMetastatic Solid Tumor+2 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd110 enrolled2 locationsNCT07156253
Recruiting
Phase 1
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Breast CancerOvarian CancerProstate Cancer+4 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd30 enrolled2 locationsNCT06666270
Recruiting
Phase 1Phase 2
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
Advanced Unresectable or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.528 enrolled1 locationNCT06555068
Recruiting
Phase 1Phase 2
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
HR Positive HER2 Negative Advanced Breast Cancer
TYK Medicines, Inc180 enrolled2 locationsNCT06950086
Recruiting
Phase 2
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
Locally Advanced or Metastatic Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.180 enrolled1 locationNCT06439771
Recruiting
Phase 2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Breast CancerBreast NeoplasmHER2-negative Breast Cancer+2 more
Fudan University620 enrolled1 locationNCT05594095
Recruiting
Phase 3
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Advanced Breast CancerHR+/HER2- Breast Cancer
Fudan University184 enrolled1 locationNCT06447623
Recruiting
Phase 2
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
Breast CancerAdvanced Breast Cancer
Fudan University265 enrolled1 locationNCT05949541